ライフサイエンスコーパス: chlorthalidone

1 signed to receive amlodipine, lisinopril, or chlorthalidone.

2 ted in independent participants treated with chlorthalidone.

3 e/bicarbonate exchange with acetazolamide or chlorthalidone.

4 -responders to hydrochlorothiazide (HCTZ) or chlorthalidone.

5 Hg higher than that in patients assigned to chlorthalidone.

6 to be twice as high with doxazosin than with chlorthalidone.

7 Chlorthalidone (12.5 to 25 mg/d) or doxazosin (2 to 8 mg

8 ve drug therapy, in which the step 1 drug is chlorthalidone (12.5-25 mg) or matching placebo, and the

9 sinopril (10-40 mg/d) arms compared with the chlorthalidone (12.5-25 mg/d) arm.

10 ndomized to placebo or active treatment with chlorthalidone (12.5-25 mg/d), with atenolol (25-50 mg/d

11 ctive treatment group received a low dose of chlorthalidone (12.5-25.0 mg/d) with a step-up to atenol

12 ed after a baseline period and after 2 wk of chlorthalidone (25 mg), amiloride (5 mg), and the two di

13 lcium antagonist (amlodipine), (4) diuretic (chlorthalidone), (5) alpha1-antagonist (doxazosin), and

14 eline diabetes, incident diabetes (7.5% with chlorthalidone, 5.6% with amlodipine, and 4.3% with lisi

15 he CC genotype showed larger reductions with chlorthalidone (-6.5 mm Hg) than with amlodipine (-3.8 m

16 Treatment with low-dose chlorthalidone, 6.25 mg daily, significantly reduced mea

17 This study compared chlorthalidone, 6.25 mg daily, with HCTZ, 12.5 mg daily,

18 with stage 1 hypertension to receive either chlorthalidone, 6.25 mg, (n = 16); HCTZ 12.5 mg (n = 18)

19 Thus, low-dose chlorthalidone, 6.25 mg, could be used as monotherapy fo

20 Chlorthalidone alone (P < 0.002) and the combination of

21 0% of subjects were receiving treatment with chlorthalidone alone by the end of years 1 and 3, respec

22 Chlorthalidone also reduced the incidence of new-onset H

23 /79, 139/79, and 140/80 mm Hg in those given chlorthalidone, amlodipine, and lisinopril.

24 Medications included chlorthalidone, amlodipine, carvedilol, cholecalciferol,

25 ermined in 37 939 participants randomized to chlorthalidone, amlodipine, lisinopril, or doxazosin tre

26 isk hypertensive patients were randomized to chlorthalidone, amlodipine, lisinopril, or doxazosin, pr

27 Random assignment to chlorthalidone, amlodipine, or lisinopril.

28 et, death occurred in 29.2% of participants (chlorthalidone/amlodipine/lisinopril) with new-onset HFP

29 one alone (P < 0.002) and the combination of chlorthalidone and amiloride (P < 0.003) reduced calcium

30 the TT homozygous individuals when comparing chlorthalidone and amlodipine (CHD: CC = 0.86; TC = 0.90

31 .8 and 11.7 mg/dL], respectively), less with chlorthalidone and placebo (0.12 and 0.13 mmol/L [4.5 an

32 for amlodipine and lisinopril compared with chlorthalidone, and 10-year adjusted rates of 86%, 87%,

33 azolamide, ethoxyzolamide, dichlorphenamide, chlorthalidone, and furosemide were not effective in viv

34 s in PC12 cells; and (3) that acetazolamide, chlorthalidone, and the neurosteroid, allopregnanolone,

35 revent Heart Attack Trial (ALLHAT), low-dose chlorthalidone as the first-line drug was superior to do

36 1985 and 1990, antihypertensive therapy with chlorthalidone-based stepped-care therapy resulted in a

37 ferentially expressed in relation to HCTZ or chlorthalidone BP response in whites.

38 d nighttime BP (p < 0.01) were observed with chlorthalidone but not with HCTZ.

39 With chlorthalidone, calcium excretion fell to normal (<4.0 m

40 e increases in plasma total cholesterol with chlorthalidone compared with placebo at 12 months were n

41 compare HCTZ with the uncommonly prescribed chlorthalidone (CTDN) in reducing cardiovascular events

42 tment initiated with doxazosin compared with chlorthalidone doubled the risk for heart failure in hig

43 1; median follow-up, 1.74 years); and in the chlorthalidone/doxazosin comparison that was terminated

44 ive risks of amlodipine or lisinopril versus chlorthalidone during year 1 were 2.22 (1.69 to 2.91; <0

45 on, stepped-care treatment based on low-dose chlorthalidone exerted a strong protective effect in pre

46 acetaminophen, ibuprofen) to not degradable (chlorthalidone, fluconazole).

47 , when mean plasma total cholesterol for the chlorthalidone group fell below baseline.

48 systolic ABP was significantly lower in the chlorthalidone group than in the the HCTZ group.

49 (HR, 1.46; 95% CI, 1.09-1.96), but those on chlorthalidone had significantly lower risk than those o

50 ent AF or atrial flutter (AFL) compared with chlorthalidone in a large clinical trial cohort with ext

51 as reduced by chlorthalidone (P <.04) and by chlorthalidone in combination with amiloride (P <.02).

52 As typically prescribed, chlorthalidone in older adults was not associated with f

53 Lisinopril was similar to chlorthalidone in preventing CHD (15.1% vs. 15.2%, respe

54 her amlodipine nor lisinopril is superior to chlorthalidone in preventing CHD, stroke, or combined CV

55 Amlodipine was similar to chlorthalidone in reducing CHD (16.0% vs. 15.2%, respect

56 was not superior to thiazide-like diuretic (chlorthalidone) in preventing coronary heart disease (CH

57 Chlorthalidone is a potent, long-acting thiazide-like di

58 failure while taking doxazosin compared with chlorthalidone is attenuated but not eliminated by addin

59 preventing CHD, stroke, or combined CVD, and chlorthalidone is superior to both for preventing heart

60 coronary heart disease, was identical in the chlorthalidone, lisinopril, and amlodipine groups.

61 pulated assessment of the relative effect of chlorthalidone, lisinopril, and amlodipine in preventing

62 Some evidence suggests that chlorthalidone may be superior to hydrochlorothiazide fo

63 ere randomly assigned to receive a diuretic (chlorthalidone; n = 13,860), a calcium antagonist (amlod

64 6 years or older who were newly treated with chlorthalidone or hydrochlorothiazide and were not hospi

65 Mean citrate excretion was reduced by chlorthalidone (P <.04) and by chlorthalidone in combina

66 ted in independent participants treated with chlorthalidone (P=0.04).

67 s initially prescribed 12.5, 25, or 50 mg of chlorthalidone per day with those prescribed 12.5, 25, o

68 Compared with chlorthalidone, randomization to either lisinopril (haza

69 Each chlorthalidone recipient was matched to up to 2 hydrochl

70 During follow-up, chlorthalidone recipients (n = 10 384) experienced the p

71 Chlorthalidone reduced the risk of HFPEF compared with a

72 Chlorthalidone reduced the risk of HFREF compared with a

73 tan, but not with the thiazide-type diuretic chlorthalidone, restored sympatholysis in the hypertensi

74 pertension, thiazide diuretics, particularly chlorthalidone, should be considered as one of the initi

75 In ALLHAT, with adjudicated outcomes, chlorthalidone significantly reduced the occurrence of n

76 igned to receive treatment with 12.5 mg/d of chlorthalidone (step 1); either 25 mg/d of atenolol or 0

77 tment of isolated systolic hypertension with chlorthalidone stepped-care therapy for 4.5 years was as

78 In patients with Dent's disease during chlorthalidone therapy, the supersaturation ratios for c

79 alyses of participants continuing to receive chlorthalidone throughout the 4 years of follow-up indic

80 Half of the rats had chlorthalidone (Thz; 4 to 5 mg/kg per d) added to their

81 Low-dose diuretic-based (chlorthalidone) treatment is effective in preventing maj

82 Compared with chlorthalidone, treatment with lisinopril is not associa

83 HF risk decreased with chlorthalidone versus amlodipine or lisinopril use durin

84 sequently, risk for those individuals taking chlorthalidone versus amlodipine remained decreased but

85 risk for heart failure with doxazosin versus chlorthalidone was 3.10 (CI, 2.51 to 3.82) and 1.42 (CI,

86 Chlorthalidone was similar to lisinopril with regard to

87 P values) of amlodipine or lisinopril versus chlorthalidone were 1.35 (1.21 to 1.50; <0.001) and 1.11

88 Patients treated with chlorthalidone were more likely to be hospitalized with

89 Participants on chlorthalidone with incident diabetes versus no diabetes

90 st the hypothesis that the thiazide diuretic chlorthalidone would decrease urine calcium excretion, s